Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety

Lignende værker

• Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
  af: Kasichayanula, Sreeneeranj, et al.
  Udgivet: (2018)
• Population pharmacokinetics and exposure–response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia
  af: Kuchimanchi, Mita, et al.
  Udgivet: (2018)
• Effect of evolocumab on cholesterol synthesis and absorption
  af: Peach, Matthew, et al.
  Udgivet: (2016)
• Evaluation of Evolocumab (AMG 145), a Fully Human Anti‐PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment
  af: Gibbs, John P., et al.
  Udgivet: (2016)
• Impact of Target‐Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
  af: Gibbs, John P., et al.
  Udgivet: (2016)